Therapeutic Asset Ratings

91,564 assets · 7,904 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
Deutetrabenazine Choreatic Disease	Teva Branded Pharmaceutical Products R&D LLC	P4	BBB (76)
Deutetrabenazine Huntington Disease	Teva Branded Pharmaceutical Products R&D LLC	P4	BBB (76)
Dexmedetomidine Neuralgia	Universidad Juárez Autónoma de Tabasco	P4	BBB (76)
Dolutegravir HIV Infectious Disease	Instituto Mexicano del Seguro Social	P4	BBB (76)
Elexacaftor Cystic Fibrosis	Meyer Children's Hospital IRCCS	P4	BBB (76)
Escitalopram Dysthymic Disorder	Nova Scotia Health Authority	P4	BBB (76)
Factor Viii (Human) Hemophilia A	Hoffmann-La Roche	P4	BBB (76)
Fitusiran Hemophilia A	Sanofi	P4	BBB (76)
Folic Acid Hyperhomocysteinemia	Shenzhen Ausa Pharmed Co.,Ltd	P4	BBB (76)
Gardasil 9 Vaccine Human Papilloma Virus Infection	Eunice Dube	P4	BBB (76)
Idarubicin Adult Acute Lymphoblastic Leukemia	Shanxi Bethune Hospital	P4	BBB (76)
Immunoglobulin G1, Anti-(Humanized Mouse Monoclonal Hr3 .Beta.1 Chain Anti-Human Epidermal Growth Factor Receptor), Disulfide With Humanized Mouse Monoclonal Hr3 .Kappa.-Chain, Dimer Malignant Pancreatic Neoplasm	Chinese PLA General Hospital	P4	BBB (76)
Isocyclophosphamide Primary Mediastinal Large B-Cell Lymphoma	David Bond, MD	P4	BBB (76)
Lidocaine Post-Operative Pain, Non-Human Animal	Instituto Mexicano del Seguro Social	P4	BBB (76)
Liraglutide Cardiovascular Disorder	University of Sao Paulo General Hospital	P4	BBB (76)
Losartan Hypertensive Disorder	Rong Zhang	P4	BBB (76)
Lurasidone Schizophrenia	Aziende Chimiche Riunite Angelini Francesco S.p.A	P4	BBB (76)
Melphalan Diffuse Large B-Cell Lymphoma	Ruijin Hospital	P4	BBB (76)
Metformin Type 2 Diabetes Mellitus	Myopharm Limited	P4	BBB (76)
Metformin Glucose Metabolism Disease	SINA Health Education and Welfare Trust	P4	BBB (76)
Methylphenidate Attention Deficit-Hyperactivity Disorder	Hugo W. Moser Research Institute at Kennedy Krieger, Inc.	P4	BBB (76)
Nivestim Neutropenia	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	P4	BBB (76)
Ocrelizumab Relapsing-Remitting Multiple Sclerosis	Biocad	P4	BBB (76)
Ocrelizumab Primary Progressive Multiple Sclerosis	Indapta Therapeutics, INC.	P4	BBB (76)
Omalizumab Allergic Asthma	Qianfoshan Hospital	P4	BBB (76)

Showing 226 to 250 of 42,327 assets

PreviousPage 10 of 1694Next